ALC vs SOLV
Alcon Inc. and Solventum, both Healthcare
Alcon Inc. is the larger company at $33B against $13B. On trailing earnings SOLV is the cheaper of the two at a P/E of 10.7 against 48.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year SOLV returned +17% against -17% for ALC. The RyuScore puts SOLV ahead, 69 against 51 out of 100.
| Figure | ALC | SOLV |
|---|---|---|
| Last close | $64.11 | $87.38 |
| Market cap | $33B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 48.2 | 10.7 |
| 1-year return | -17% | +17% |
| 5-year return | -25% | n/a |
| RyuScoresector-relative, 1–10 | 51/100 | 69/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alcon Inc.
Revenue of $5.3B in H2 2025, net income $454M.
Solventum
Revenue of $2.2B in Q2 2026, net income $92M. Its largest reported line is Med Surg, 42% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.